This information was published on 2026-01-15T00:07:51 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2583203 |
| (220) |
03 Sep 2025
|
| (300) |
US, 14 Aug 2025, 99336893
|
| (511) (510) |
Class 5
Technologies in the nature of pharmaceutical preparations of drugs that facilitate the delivery of pharmaceutical compounds for oral administration of therapeutics utilizing the lymphatic system to treat human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, neuropsychiatric disorders, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan diseases. Class 35 Commercialization, namely, commercial consultancy in the pharmaceutical and biotechnology fields. Class 42 Research and development in the pharmaceutical and biotechnology fields; medical and scientific research in the field of clinical trials. |
| (540) | GLYPHAGO |
| (550) | Word |
| (730) |
Seaport Therapeutics, Inc.
|
| (750) |
Davies Collison Cave Pty Ltd
|
Find out more about publications on the About page.